Angiopoietin-like 3

Angiopoietin-like 3

Angiopoietin-like 3 詳細

Molecule Name
Angiopoietin like 3
分子の別称
ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2
Drug Development Progress
治験薬の数14
市販薬剤の数1
研究&開発段階Approved
ターゲットの別称
Angiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
バックグランド
Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Angiopoietin-like 3 製品リスト

Species
  • Human(4)
  • Mouse(1)
Tag
  • His Tag(3)
  • Fc Tag(1)
  • His Tag & Avi Tag(1)
Host
  • HEK293(5)
Conjugate
  • Unconjugated(4)
  • Biotin-labeled(1)
Grade
  • RUO(5)
Low Endotoxin
  • No(5)
You Have Viewed 1-5 Of 5 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
ZodasiranARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals)Phase 3 ClinicalRoche Ltd
Dyslipidemias; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypertriglyceridemia
詳細
LNA-043LNA-043Phase 2 ClinicalNovartis Pharma Ag
Knee Injuries; Osteoarthritis; Osteoarthritis, Knee
詳細
VupanorsenISIS-703802; PF-07285557Phase 2 ClinicalIonis Pharmaceuticals Inc
Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Homozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
詳細
EDP-167EDP-167; EDP167Phase 2 ClinicalEteng Pharmaceutical (Zhuhai) Co Ltd
Dyslipidemias; Homozygous familial hypercholesterolemia
詳細
ALN-ANG3ALN-ANG3Phase 2 ClinicalAlnylam Pharmaceuticals Inc
Diabetic Nephropathies
詳細
BW-00112BW-00112; BW00112Phase 2 ClinicalShanghai Argo Biopharmaceutical Co Ltd
Dyslipidemias; Hypertriglyceridemia
詳細
SolbinsiranLY-3561774; DCR-CM-1; DCR-CM1Phase 2 ClinicalDicerna Pharmaceuticals Inc
Cardiovascular Diseases; Dyslipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases
詳細
JS-401JS-401; RP-912Phase 1 ClinicalRisen (Suzhou) Pharma Tech Co Ltd
Hyperlipidemias; Metabolic Diseases
詳細
VERVE-201VERVE-201Phase 1 ClinicalBroad Institute, Harvard University
Atherosclerosis; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia
詳細
SYH-2070SYH2070; SYH-2070Phase 1 ClinicalCspc Heibei Zhongrun Pharmaceutiacl Co Ltd
Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia
詳細
NN-6491NN6491; NN-6491Phase 1 ClinicalNovo Nordisk A/S
Cardiovascular Diseases
詳細
NNC0491-6075NNC0491-6075; NNC04916075Phase 1 ClinicalNovo Nordisk A/S
Dyslipidemias
詳細
AZD-1705AZD1705; AZD-1705Phase 1 ClinicalAstrazeneca Plc, Parexel International Corp
Cardiovascular Diseases
詳細
CTX-310CTX-310; CTX310Phase 1 ClinicalCrispr Therapeutics Ag
Cardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases; Sitosterolemia
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
EvinacumabREGN-1500ApprovedRegeneron Pharmaceuticals IncEvkeezaUnited StatesHypercholesterolemia; Homozygous familial hypercholesterolemiaRegeneron Pharmaceuticals Inc2021-02-11
Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia; Metabolic Diseases
詳細
Customer Reviews